The joint modelling strategy for dynamic prediction utilizes joint information on tumor shrinkage and PSA measurements, allowing it to make updated predictions for PCa patients, aiming to provide patient-specific trajectories of PCa progression and time-to-event (TTE) data. The gene discussed is KLK3; the disease is neoplasm.